NICE
NICE Recommends AstraZeneca's Imfinzi for PD-L1-Positive NSCLC
The agency recommended that NHS England make the immunotherapy available based on data from the Phase III PACIFIC trial.
NICE Recommends Merck's Tepmetko for NSCLC Patients With METex14 Skipping Mutation
More than 700 people in England are now eligible to receive Tepmetko as either a first- or second-line treatment.Â
NICE Recommends Against Piqray Combo for PIK3CA-Mutated Metastatic Breast Cancer
The committee said it saw no direct evidence in favor of Piqray-fulvestrant when comparing it against standard treatments and found the cost-effectiveness estimates too high.
NHS England Expediting Access to Takeda's Exkivity for Certain NSCLC Patients
The agency brokered a deal between NICE and Takeda, under which the sponsor will provide the drug on a budget-neutral basis while NICE completes its appraisal.
UK's NICE Recommends Against Merck's Keytruda, Chemo Combo for Advanced PD-L1-Positive TNBC
In a draft guidance, the committee raised concerns about the lack of evidence comparing Keytruda-chemo to Tecentriq-chemo, which is already available for patients in England.